WASHINGTON, DC — The Drug Enforcement Administration (DEA) has emergency scheduled bromazolam, a potent synthetic benzodiazepine that has flooded the illicit drug market. Effective immediately, the substance is classified as Schedule I under the Controlled Substances Act, the most restrictive category, signaling high potential for abuse and no accepted medical use.
A Rapidly Evolving Threat
Bromazolam is frequently used to manufacture counterfeit Xanax tablets. The DEA acted swiftly to address what it calls a “rapidly evolving threat.”
“The emergency scheduling of bromazolam is a decisive step to get ahead of a rapidly evolving threat. We will not wait for more lives to be put at risk,” said Cheri Oz, Assistant Administrator of the DEA’s Diversion Control Division.
The substance is now one of the most frequently identified benzodiazepines in illicit drug seizures nationwide. It is often mixed with lethal opioids like fentanyl, a combination that significantly increases the risk of fatal respiratory depression.
The local impact for Brunswick, Columbus and Horry Counties of this federal action is immediate across the Carolinas:
-
Counterfeit “Xanax” Warning: Local law enforcement warns residents that “white bars” sold on the street as Xanax frequently contain bromazolam instead of alprazolam. These pills are visually indistinguishable from legitimate pharmaceuticals.
-
Widespread Detection: North Carolina health data confirms the presence of “novel benzodiazepines,” including bromazolam, in fatal overdoses across 33 counties. These drugs have infiltrated every corner of the tri-county region (Brunswick, Columbus, and Horry).
-
The “Benzo-Dope” Crisis: The rise of “benzo-dope”—fentanyl mixed with synthetic benzos like bromazolam poses a unique danger. Naloxone (Narcan) does not reverse the effects of bromazolam, making these overdoses exceptionally difficult to treat.
By placing bromazolam in Schedule I, the DEA has triggered strict regulatory controls. Manufacture, distribution, or possession now carries high-level administrative, civil, and criminal sanctions. Adverse health effects include slurred speech, loss of bodily control (ataxia), altered mental state, and severe respiratory depression.
This emergency scheduling is a temporary order effective for two years, ending March 16, 2028. During this period, the DEA and the Department of Health and Human Services (HHS) will conduct a formal scientific and medical evaluation. While the order is technically “temporary,” it carries the full weight of federal law, and the DEA maintains the authority to make the Schedule I placement permanent following the review.
© 2026 BCDollarSaver.com. All rights reserved.
Be the first to comment